Shabbir Anik 4

4 · SUTRO BIOPHARMA, INC. · Filed Mar 7, 2023

Form 4

Period: 2023-03-03

Chief Technical Ops. Officer

Transactions

Exercise/Conversion
Common Stock
2023-03-03+7,875→ 38,299 total
Exercise/Conversion
Common Stock
2023-03-03+8,750→ 47,049 total
Tax Payment
Common Stock
2023-03-03$5.79/sh−6,222$36,025→ 40,827 total
Award
Restricted Stock Unit (RSU)
2023-03-03+40,000→ 40,000 total
Exp: 2025-03-01→ Common Stock (40,000 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2023-03-03−7,875→ 23,625 total
Exp: 2026-03-04→ Common Stock (7,875 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2023-03-03−8,750→ 17,500 total
Exp: 2025-03-05→ Common Stock (8,750 underlying)

Footnotes (5)

[F1]Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
[F2]Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
[F3]The RSUs vest as to 1/2 of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
[F4]The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.
[F5]The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date.

Documents

1 file